News
- Roflumilast: a novel approach to the management of COPD
- Published on May 28, 2009
Nycomed have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for roflumilast (Daxas) as a once-daily oral treatment for patients with COPD associated with chronic bronchitis.
- CYT006-AngQb fails to reduce blood pressure in phase IIa study
- Published on May 12, 2009
A double-blind, placebo-controlled, phase IIa study has failed to demonstrate that Cytos Biotechnology’s hypertension vaccine, CYT006-AngQb, is effective in reducing blood pressure. An earlier phase IIa trial with the candidate vaccine had demonstrated clinically relevant and statistically significant blood pressure reductions, and as such the company are examining the new data in detail to try to explain and understand the negative result.
- New data for lipid modifying drug
- Published on May 12, 2009
A recent phase III study has found that patients with primary hypercholesterolaemia or mixed dyslipidaemia experienced reduced LDL-C of almost 48%, increased HDL-C of almost 28% and reduced triglyceride (TG) levels of about 33% after 12 weeks treatment with a combination of Tredaptive 2g (nicotinic acid/ laropiprant) and simvastatin (pooled across 20mg or 40mg).
- Molecular discovery by BBSRC researchers may lead to a new drug class for type 2 diabetes
- Published on May 12, 2009
Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have harnessed a novel drug-discovery tool to identify a new molecule involved in the body’s insulin secretion process, a finding which could lead to a new drug class for the treatment of type 2 diabetes.
- Sutent receives NICE recommendation
- Published on May 12, 2009
NICE has recommended Pfizer’s sunitinib (Sutent) as first-line therapy for kidney cancer. The drug, which was initially rejected on cost-effectiveness grounds in August 2008, can be used in patients in England who have either advanced or metastatic renal cell carcinoma or both, as long as they are suitable for immunotherapy and are well enough to tolerate it. The drug can also be considered for renal cell carcinoma in patients who are having or have had interferon-alpha or interleukin-2 before these...